Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Malaria Journal
Published in: Malaria Journal 1/2016

Open Access 01-12-2016 | Research

Plasmodium vivax msp-3α polymorphisms: analysis in the Indian subcontinent

Authors: Anju Verma, Hema Joshi, Vineeta Singh, Anup Anvikar, Neena Valecha

Published in: Malaria Journal | Issue 1/2016

Login to get access

Abstract

Background

Plasmodium vivax is the most widely distributed human malaria parasite and accounts for approximately the same number of malaria cases as Plasmodium falciparum in India. Compared with P. falciparum, P. vivax is difficult to eradicate because of its tendency to cause relapses, which impacts treatment and control strategies. The genetic diversity of these parasites, particularly of the merozoite surface protein-3 alpha (msp-3α) gene, can be used to help develop a potential vaccine. The present study aimed to investigate the genetic diversity of P. vivax using the highly polymorphic antigen gene msp-3α and to assess the suitability of using this gene for population genetic studies of P. vivax isolates and was carried out in 2004–06. No recent study has been reported for MSP 3α in the recent decade in India. Limited reports are available on the genetic diversity of the P. vivax population in India; hence, this report aimed to improve the understanding of the molecular epidemiology of the parasite by studying the P. vivax msp-3α (Pvmsp-3α) marker from P. vivax field isolates from India.

Methods

Field isolates were collected from different sites distributed across eight states in India. A total of 182 blood samples were analysed by a nested polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique using the HhaI and AluI restriction enzymes to determine genetic msp-3α variation among clinical P. vivax isolates.

Results

Based on the length variants of the PCR products of Pvmsp-3α gene, three allele sizes, Type A (1.8 kb), Type B (1.5 kb) and Type C (1.2 kb) were detected among the 182 samples. Type A PCR amplicon was more predominant (75.4 %) in the samples compared with the Type B (14.3 %) and Type C (10.0 %) polymorphisms. Among all of the samples analysed, 8.2 % were mixed infections detected by PCR alone. Restriction fragment length polymorphism (RFLP) analysis involving the restriction enzymes AluI and HhaI generated fragment sizes that were highly polymorphic and revealed substantial diversity at the nucleotide level.

Conclusions

The present study is the first extensive study in India using the Pvmsp-3α marker. The results indicated that Pvmps-3α, a polymorphic genetic marker of P. vivax, exhibited considerable variability in infection prevalence in field isolates from India. Additionally, the mean multiplicity of infection observed at all of the study sites indicated that P. vivax is highly diverse in nature in India, and Pvmsp-3α is likely an effective and promising epidemiological marker.
Appendix
Available only for authorised users
Literature
1.
2.
Naing C, Whittaker MA, Wai VN, Mak JW. Is Plasmodium vivax malaria a severe malaria?: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2014;8:e3071.CrossRefPubMedPubMedCentral
3.
Khattak AA, Venkatesan M, Nadeem MF, Satti HS, Yaqoob A, Strauss K, et al. Prevalence and distribution of human Plasmodium infection in Pakistan. Malar J. 2013;12:297.CrossRefPubMedPubMedCentral
4.
Raza A, Ghanchi NK, Thaver AM, Jafri S, Beg MA. Genetic diversity of Plasmodium vivax clinical isolates from southern Pakistan using pvcsp and pvmsp1 genetic markers. Malar J. 2013;12:16.CrossRefPubMedPubMedCentral
5.
Baird JK, Basri H, Bangs MJ, Subianto B, Patchen LC, Hoffman SL. Resistance to chloroquine by Plasmodium vivax in Irian Jaya Indonesia. Am J Trop Med Hyg. 1991;44:547–52.PubMed
6.
Garg M, Gopinathan N, Bodhe P, Kshirsagar NA. Vivax malaria resistant to chloroquine: case reports from Bombay. Trans R Soc Trop Med Hyg. 1995;89:656–7.CrossRefPubMed
7.
Dua VK, Kar PK, Sharma VP. Chloroquine resistant Plasmodium vivax malaria in India. Trop Med Int Health. 1996;1:816–9.CrossRefPubMed
8.
Kshirsagar NA, Gogtay NJ, Rajgor D, Dalvi SS, Wakde M. An unusual case of multidrug-resistant Plasmodium vivax malaria in Mumbai (Bombay) India. Ann Trop Med Parasitol. 2000;94:189–90.CrossRefPubMed
9.
Singh RK. Emergence of chloroquine-resistant vivax malaria in south Bihar (India). Trans R Soc Trop Med Hyg. 2000;94:327.CrossRefPubMed
10.
Soto J, Toledo J, Gutierrez P, Luzz M, Llinas N, Cedeno N, et al. Plasmodium vivax clinically resistant to chloroquine in Colombia. Am J Trop Med Hyg. 2001;65:90–3.PubMed
11.
Nandy A, Addy M, Maji AK, Bandyopadhyay AK. Monitoring the chloroquine sensitivity of Plasmodium vivax from Calcutta and Orissa, India. Ann Trop Med Parasitol. 2003;97:215–20.CrossRefPubMed
12.
Gonçalves LA, Cravo P, Ferreira MU. Emerging Plasmodium vivax resistance to chloroquine in South America: an overview. Mem Inst Oswaldo Cruz. 2014;109:534–9.CrossRefPubMedPubMedCentral
13.
14.
Singh V, Mishra N, Awasthi G, Dash AP, Das A. Why is it important to study malaria epidemiology in India? Trends Parasitol. 2009;25:452–7.CrossRefPubMed
15.
Breman JG, Alilio MS, White NJ. Defining and defeating the intolerable burden of malaria III. Progress and perspectives. Am J Trop Med Hyg. 2007;77(6 Suppl):vi–xi.
16.
Arnott A, Barry AE, Reeder JC. Understanding the population genetics of Plasmodium vivax is essential for malaria control and elimination. Malar J. 2012;11:14.CrossRefPubMedPubMedCentral
17.
Eckhoff Philip A. Malaria parasite diversity and transmission intensity affect development of parasitological immunity in a mathematical model. Malar J. 2012;11:419.CrossRefPubMedPubMedCentral
18.
Neafsey DE, Galinsky K, Jiang RH, Young L, Sykes SM, Saif S, et al. The malaria parasite Plasmodium vivax exhibits greater genetic diversity than Plasmodium falciparum. Nat Genet. 2012;44:1046–50.CrossRefPubMedPubMedCentral
19.
Hisaeda H, Yasutomo K, Himeno K. Malaria: immune evasion by parasites. Int J Biochem Cell Biol. 2005;37:700–6.CrossRefPubMed
20.
Kim JR, Imwong M, Nandy A, Chotivanich K, Nontprasert A, Tonomsing N, et al. Genetic diversity of Plasmodium vivax in Kolkata, India. Malar J. 2006;5:71.CrossRefPubMedPubMedCentral
21.
Prajapati SK, Joshi H, Valecha N. Plasmodium vivax merozoite surface protein-3 [alpha]: a high-resolution marker for genetic diversity studies. J Vector Borne Dis. 2010;47:85–90.PubMed
22.
Rajesh V, Elamaran M, Vidya S, Gowrishankar M, Kochar D, Das A. Plasmodium vivax: genetic diversity of the apical membrane antigen-1 (AMA-1) in isolates from India. Exp Parasitol. 2007;116:252–6.CrossRefPubMed
23.
Farooq U, Malla N, Dubey ML. Polymorphism in merozoite surface protein-1 gene in north and northwest Indian field isolates of Plasmodium vivax. Indian J Med Res. 2009;130:736–41.PubMed
24.
25.
26.
Rayner JC, Huber CS, Feldman D, Ingravallo P, Galinski MR, Barnwell JW. Plasmodium vivax merozoite surface protein PvMSP-2 beta is radically polymorphic through mutation and large insertions and deletions. Infect Genet Evol. 2004;4:309–19.CrossRefPubMed
27.
Rayner JC, Corredor V, Feldman D, Ingravallo P, Iderabdullah F, Galinski MR, et al. Extensive polymorphism in the Plasmodium vivax merozoite surface coat protein MSP-3α is limited to specific domains. Parasitology. 2002;125:393–405.CrossRefPubMed
28.
Rice BL, Acosta MM, Pacheco MA, Carlton JM, Barnwell JW, Escalante AA. The origin and diversification of the merozoite surface protein 3 (msp3) multi-gene family in Plasmodium vivax and related parasites. Mol Phylogenet Evol. 2014;78:172–84.CrossRefPubMedPubMedCentral
29.
Carlton JM, Adams JH, Silva JC, Bidwell SL, Lorenzi H, Caler E, et al. Comparative genomics of the neglected human malaria parasite Plasmodium vivax. Nature. 2008;455:757–63.CrossRefPubMedPubMedCentral
30.
McColl DJ, Anders RF. Conservation of structural motifs and antigenic diversity in the Plasmodium falciparum merozoite surface protein-3 (MSP-3). Mol Biochem Parasitol. 1997;90:21–31.CrossRefPubMed
31.
Nam HW, Song KJ, Ahn HJ, Yang Z, Chong CK, Cho PY, et al. Probability of antibody formation against circumsporozoite protein of Plasmodium vivax among Korean malaria patients. Korean J Parasitol. 2014;52:143.CrossRefPubMedPubMedCentral
32.
Adhikari M, Ranjitkar S, Schousboe ML, Alifrangis M, Imwong M, Bhatta DR, et al. Genetic diversity of Plasmodium vivax merozoite surface protein-3alpha (Pvmsp-3alpha) gene in Jhapa District of Nepal. Southeast Asian J Trop Med Public Health. 2012;43:280–6.PubMed
33.
Khatoon L, Baliraine FN, Bonizzoni M, Malik SA, Yan G. Genetic structure of Plasmodium vivax and Plasmodium falciparum in the Bannu district of Pakistan. Malar J. 2010;9:112.CrossRefPubMedPubMedCentral
34.
Khan SN, Khan A, Khan S, Ayaz S, Attaullah S, Khan J, et al. PCR/RFLP-based analysis of genetically distinct Plasmodium vivax population of Pvmsp-3α and Pvmsp-3β genes in Pakistan. Malar J. 2014;13:355.CrossRefPubMedPubMedCentral
35.
Kibria MG, Elahi R, Mohon AN, Khan WA, Haque R, Alam MS. Genetic diversity of Plasmodium vivax in clinical isolates from Bangladesh. Malar J. 2015;14:267.CrossRefPubMedPubMedCentral
36.
Schousboe ML, Rajakaruna RS, Amerasinghe PH, Konradsen F, Ord R, Pearce R, et al. Analysis of polymorphisms in the merozoite surface protein-3α gene and two microsatellite loci in Sri Lankan Plasmodium vivax: evidence of population substructure in Sri Lanka. Am J Trop Med Hyg. 2011;85:994–1001.CrossRefPubMedPubMedCentral
37.
Rungsihirunrat K, Chaijaroenkul W, Siripoon N, Seugorn A, Na-Bangchang K. Genotyping of polymorphic marker (MSP3α and MSP3β) genes of Plasmodium vivax field isolates from malaria endemic of Thailand. Trop Med Int Health. 2011;16:794–801.CrossRefPubMed
38.
Gupta B, Reddy BN, Fan Q, Yan G, Sirichaisinthop J, Sattabongkot J, et al. Molecular evolution of PvMSP3α block II in Plasmodium vivax from diverse geographic origins. PLoS ONE. 2015;10:e0135396.CrossRefPubMedPubMedCentral
39.
Cui L, Mascorro CN, Fan Q, Rzomp KA, Khuntirat B, Zhou G, et al. Genetic diversity and multiple infections of Plasmodium vivax malaria in Western Thailand. Am J Trop Med Hyg. 2003;68:613–9.PubMed
40.
Mascorro CN, Zhao K, Khuntirat B, Sattabongkot J, Yan G, Escalante AA, et al. Molecular evolution and intragenic recombination of the merozoite surface protein MSP-3α from the malaria parasite Plasmodium vivax in Thailand. Parasitology. 2005;131:25–35.CrossRefPubMed
41.
Moon SU, Lee HW, Kim JY, Na BK, Cho SH, Lin K, et al. High frequency of genetic diversity of Plasmodium vivax field isolates in Myanmar. Acta Trop. 2009;109:30–6.CrossRefPubMed
42.
Nam DH, Oh JS, Nam MH, Park HC, Lim CS, Lee WJ, et al. Emergence of new alleles of the MSP-3α gene in Plasmodium vivax isolates from Korea. Am J Trop Med Hyg. 2010;82:522–4.CrossRefPubMedPubMedCentral
43.
Wickramarachchi T, Premaratne PH, Dias S, Handunnetti SM, Udagama-Randeniya PV. Genetic complexity of Plasmodium vivax infections in Sri Lanka, as reflected at the merozoite-surface-protein-3alpha locus. Ann Trop Med Parasitol. 2010;104:95–108.CrossRefPubMed
44.
Han ET, Song TE, Park JH, Shin EH, Guk SM, Kim TY, et al. Allelic dimorphism in the merozoite surface protein-3α in Korean isolates of Plasmodium vivax. Am J Trop Med Hyg. 2004;71:745–9.PubMed
45.
Cui L, Escalante AA, Imwong M, Snounou G. The genetic diversity of Plasmodium vivax populations. Trends Parasitol. 2003;19:220–6.CrossRefPubMed
46.
Stanisic DI, Javati S, Kiniboro B, Lin E, Jiang J, Singh B, et al. Naturally acquired immune responses to P. vivax merozoite surface protein 3α and merozoite surface protein 9 are associated with reduced risk of P. vivax malaria in young Papua New Guinean children. PLoS Negl Trop Dis. 2013;7:e2498.CrossRefPubMedPubMedCentral
47.
48.
Bruce MC, Galinski MR, Barnwell JW, Snounou G, Day KP. Polymorphism at the merozoite surface protein-3alpha locus of Plasmodium vivax: global and local diversity. Am J Trop Med Hyg. 1999;61:518–25.PubMed
49.
50.
51.
Kimura M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol. 1980;16:111–20.CrossRefPubMed
52.
53.
Gantait K, Gantait I. Vivax malaria complicated by myocarditis. J Assoc Physicians India. 2013;61:944–5.PubMed
54.
55.
Ord R, Polley S, Tami A, Sutherland CJ. High sequence diversity and evidence of balancing selection in the Pvmsp3α gene of Plasmodium vivax in the Venezuelan Amazon. Mol Biochem Parasit. 2005;144:86–93.CrossRef
56.
Rayment JH, Forsdyke DR. Amino acids as placeholders. Appl Bioinform. 2005;4:117–30.CrossRef
57.
Sutton PL, Neyra V, Hernandez JN, Branch OH. Plasmodium falciparum and Plasmodium vivax infections in the Peruvian Amazon: propagation of complex, multiple allele-type infections without super-infection. Am J Trop Med Hyg. 2009;81:950–60.CrossRefPubMedPubMedCentral
58.
Cristiano FA, Pérez MA, Nicholls RS, Guerra AP. Polymorphism in the Plasmodium vivax msp 3: gene in field samples from Tierralta, Colombia. Mem Inst Oswaldo Cruz. 2008;103:493–6.CrossRefPubMed
59.
Li YC, Wang GZ, Meng F, Zeng W, He CH, Hu XM, et al. Genetic diversity of Plasmodium vivax population before elimination of malaria in Hainan Province, China. Malar J. 2015;14:78.CrossRefPubMedPubMedCentral
60.
Taylor JE, Pacheco MA, Bacon DJ, Beg MA, Machado RL, Fairhurst RM, et al. The evolutionary history of Plasmodium vivax as inferred from mitochondrial genomes: parasite genetic diversity in the Americas. Mol Biol Evol. 2013;30:2050–64.CrossRefPubMedPubMedCentral
61.
Koepfli C, Rodrigues PT, Antao T, Orjuela-Sanchez P, Van den Eede P, Gamboa D, et al. Plasmodium vivax diversity and population structure across four continents. PLoS Negl Trop Dis. 2015;9:e0003872.CrossRefPubMedPubMedCentral
62.
Jennison C, Arnott A, Tessier N, Tavul L, Koepfli C, Felger I, et al. Plasmodium vivax populations are more genetically diverse and less structured than sympatric Plasmodium falciparum populations. PLoS Negl Trop Dis. 2015;9:e0003634.CrossRefPubMedPubMedCentral
63.
Zakeri S, Barjesteh H, Djadid ND. Merozoite surface protein-3α is a reliable marker for population genetic analysis of Plasmodium vivax. Malar J. 2006;5:53.CrossRefPubMedPubMedCentral
64.
Maneerattanasak S, Gosi P, Krudsood S, Tongshoob J, Lanteri CA, Snounou G, et al. Genetic diversity among Plasmodium vivax isolates along the Thai–Myanmar border of Thailand. Malar J. 2016;15:75.CrossRefPubMedPubMedCentral
65.
Kolakovich KA, Ssengoba A, Wojcik K, Tsuboi T, Al-Yaman F, Alpers M, et al. Plasmodium vivax: favored gene frequencies of the merozoite surface protein-1 and the multiplicity of infection in a malaria endemic region. Exp Parasitol. 1996;83:11–8.CrossRefPubMed
66.
Joshi H, Valecha N, Verma A, Kaul A, Mallick PK, Shalini S, et al. Genetic structure of Plasmodium falciparum field isolates in eastern and north–eastern India. Malar J. 2007;6:60.CrossRefPubMedPubMedCentral
67.
Koepfli C, Ross A, Kiniboro B, Smith TA, Zimmerman PA, Siba P, et al. Multiplicity and diversity of Plasmodium vivax infections in a highly endemic region in Papua New Guinea. PLoS Negl Trop Dis. 2011;5:e1424.CrossRefPubMedPubMedCentral
68.
Koepfli C, Colborn KL, Kiniboro B, Lin E, Speed TP, Siba PM, et al. A high force of Plasmodium vivax blood-stage infection drives the rapid acquisition of immunity in Papua New Guinean Children. PLoS Negl Trop Dis. 2013;7:e2403.CrossRefPubMedPubMedCentral
69.
Baniecki ML, Faust AL, Schaffner SF, Park DJ, Galinsky K, Daniels RF, et al. Development of a single nucleotide polymorphism barcode to genotype Plasmodium vivax infections. PLoS Negl Trop Dis. 2015;9:0003539.CrossRef
70.
Arévalo-Herrera M, Chitnis C, Herrera S. Current status of Plasmodium vivax vaccine. Human Vaccines. 2010;6:124–32.CrossRefPubMed
71.
Mourão LC, Morais CG, Bueno LL, Jimenez MC, Soares IS, Fontes CJ, et al. Naturally acquired antibodies to Plasmodium vivax blood-stage vaccine candidates (PvMSP-1 19 and Pvmsp-3α 359–798) and their relationship with hematological features in malaria patients from the Brazilian Amazon. Microb Infect. 2012;14:730–9.CrossRef
Metadata
Title
Plasmodium vivax msp-3α polymorphisms: analysis in the Indian subcontinent
Authors
Anju Verma
Hema Joshi
Vineeta Singh
Anup Anvikar
Neena Valecha
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2016
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/s12936-016-1524-y

Other articles of this Issue 1/2016

Malaria Journal 1/2016 Go to the issue

Research

Impact of the Mass Drug Administration for malaria in response to the Ebola outbreak in Sierra Leone

Research

Malaria prevention practices and delivery outcome: a cross sectional study of pregnant women attending a tertiary hospital in northeastern Nigeria

Research

Global priorities for research and the relative importance of different research outcomes: an international Delphi survey of malaria research experts

Research

Determinants of host feeding success by Anopheles farauti

Research

Reusing larval rearing water and its effect on development and quality of Anopheles arabiensis mosquitoes

Research

First evaluation of bendiocarb in experimental huts using different substrates in Madagascar
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits